- Home
- SNDX vs NG Comparison
SNDX vs NG Comparison
Compare SNDX & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- NG
- Stock Information
- Founded
- SNDX 2005
- NG 1984
- Country
- SNDX United States
- NG Canada
- Employees
- SNDX N/A
- NG N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- NG Precious Metals
- Sector
- SNDX Health Care
- NG Basic Materials
- Exchange
- SNDX Nasdaq
- NG Nasdaq
- Market Cap
- SNDX 1.3B
- NG 1.5B
- IPO Year
- SNDX 2016
- NG N/A
- Fundamental
- Price
- SNDX $19.91
- NG $9.59
- Analyst Decision
- SNDX Strong Buy
- NG Strong Buy
- Analyst Count
- SNDX 12
- NG 3
- Target Price
- SNDX $36.92
- NG $10.17
- AVG Volume (30 Days)
- SNDX 3.0M
- NG 2.8M
- Earning Date
- SNDX 11-03-2025
- NG 10-01-2025
- Dividend Yield
- SNDX N/A
- NG N/A
- EPS Growth
- SNDX N/A
- NG N/A
- EPS
- SNDX N/A
- NG N/A
- Revenue
- SNDX $111,304,000.00
- NG N/A
- Revenue This Year
- SNDX $636.61
- NG N/A
- Revenue Next Year
- SNDX $114.95
- NG N/A
- P/E Ratio
- SNDX N/A
- NG N/A
- Revenue Growth
- SNDX 595.65
- NG N/A
- 52 Week Low
- SNDX $8.58
- NG $2.26
- 52 Week High
- SNDX $20.08
- NG $10.90
- Technical
- Relative Strength Index (RSI)
- SNDX 72.56
- NG 63.26
- Support Level
- SNDX $16.75
- NG $8.02
- Resistance Level
- SNDX $20.08
- NG $9.30
- Average True Range (ATR)
- SNDX 1.23
- NG 0.49
- MACD
- SNDX 0.40
- NG 0.09
- Stochastic Oscillator
- SNDX 97.58
- NG 99.02
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.